CDK9-IN-26

HY-155844	
C ₁₇ H ₁₄ N ₄ O ₂	
306.32	
CDK	ŇH
Cell Cycle/DNA Damage	
Please store the product under the recommended conditions in the Certificate of Analysis.	
	C ₁₇ H ₁₄ N ₄ O ₂ 306.32 CDK Cell Cycle/DNA Damage Please store the product under the recommended conditions in the Certificate of

BIOLOGICAL ACTIVITY	
Description	CDK9-IN-26 (compound 1is a CDK9 inhibitor (IC_{50}=0.18 $\mu\text{M}) \boxtimes^{[1]}.$
IC ₅₀ & Target	IC50: 0.18 μM (CDK9) ^[1]
In Vivo	CDK9-IN-26 (compound 1d) MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Alsfouk AA, et al. New Imadazopyrazines with CDK9 Inhibitory Activity as Anticancer and Antiviral: Synthesis, In Silico, and In Vitro Evaluation Approaches. Pharmaceuticals (Basel). 2023 Jul 18;16(7):1018.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 E-mail: tech@MedChemExpress.com Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Product Data Sheet

Fax: 609-228-5909